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SUMMARY
SCN8A encodes Nav1.6, one of the main voltage-gated sodium channel subunits in the
brain, and SCN8A mutations lead to epileptic encephalopathy. Particular mutations
render the mutant channel more susceptible to inhibition by phenytoin. Yet, the
potentially severe side effects of phenytoin maintenance therapy, especially cognitive
impairment, are undesirable in these already cognitively impaired patients. We
describe a 5-year-old patient with SCN8A encephalopathy in whom phenytoin proved
successful as emergency treatment to prevent clustering of seizures and status epilep-
ticus, thus hospital stays. The ketogenic diet, levetiracetam, zonisamide, topiramate,
and phenytoinmaintenance therapy resulted in adverse reactions not previously docu-
mented in SCN8A encephalopathy.
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SCN8A encodes Nav1.6, one of the main voltage-gated
sodium channel subunits in the brain, which plays an impor-
tant role in action potential propagation and spread.1 SCN8A
mutations have been described in patients with epileptic
encephalopathy, with seizure onset before the age of
18 months, intellectual disability, and developmental
delay.2,3 Seizure type, neurodevelopment, and disease
severity vary between patients with SCN8A
encephalopathy,2 likely because distinct mutations in
SCN8A confer different effects on Nav1.6 function.4
Recently, Barker et al.5 showed that the SCN8Amutation
p.Ile1327Val is a gain-of-function mutation, resulting in
increased seizure susceptibility and rendering the mutant
channel more susceptible to inhibition by phenytoin. Hence,
phenytoin may be efficacious in SCN8A encephalopathy.
The efficacy of phenytoin in SCN8A encephalopathy has
previously been observed.3 Phenytoin is a sodium channel
blocker and binds at a receptor site in the pore of sodium
channels, decreases the sodium influx, and thereby
decreases the excitability of the neuron. The reason that
phenytoin could be an important treatment option in patients
with SCN8A-related epilepsy is that it is primarily expected
to block the increased sodium current through the mutated
Nav1.6, but not to affect the function of other voltage-gated
sodium channels not affected by the SCN8A mutation.
Given the fact that phenytoin is one of the few sodium chan-
nel blockers targeting only the sodium channel and no other
molecular targets in the brain, this might explain the
observed response to phenytoin treatment in SCN8A
encephalopathy patients, in contrast with the response to
treatment with other sodium channel blockers.3
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SHORTRESEARCHARTICLE
In a patient with the SCN8Amutation p.Val233Ile, identi-
fied by whole exome sequencing performed as described
previously,6 we have observed (1) efficacy of both intra-
venous and oral phenytoin as an emergency treatment to
prevent seizure escalation instead of maintenance therapy
and (2) undocumented adverse reactions to a ketogenic diet,
levetiracetam, zonisamide, and topiramate.
Case Report
The patient is a 5-year-old boy with hypotonia from birth,
who had his first tonic-clonic seizure at the age of 4 months.
The seizure frequency progressed over 1 year, to four sei-
zures a day. The seizure semiology was always similar and
there were no provocative factors such as fever. During this
period, his psychomotor development stagnated. A DNA
diagnostic test of the SCN1A gene revealed no mutation. Ini-
tial treatment with valproic acid and phenobarbital resulted
in seizure freedom for 1 year and resumption of psychomo-
tor development. Then, seizures recurred monthly and built
up to a status epilepticus once every 2 to 3 months, requiring
admission to the intensive care unit (ICU) and benzodi-
azepine therapy. After every status epilepticus, psychomotor
skills deteriorated, including temporary loss of speech.
Phenobarbital was switched to lamotrigine and clobazam,
without any effect on seizure frequency. Sequential neu-
ropsychological assessments revealed a decrease in total IQ
scores from 83 (verbal IQ 88, performance IQ 83) to 63
(verbal IQ 66, performance IQ 70).
Ketogenic diet was started but had to be halted because of
severe nausea and vomiting, fatigue, increased seizure fre-
quency, and encephalopathy. All improved immediately after
cessation of the diet. Seizure frequency decreased to six per
year, but all led to epileptic status with ICU admittance. Ben-
zodiazepines were no longer effective, but there was a consis-
tently good response to intravenous phenytoin administration.
Addition of levetiracetam, zonisamide, and later topira-
mate to maintenance therapy resulted in rapid deterioration,
with encephalopathy, ataxia, and dysarthria and recurrent sta-
tus epilepticus. The encephalopathy, ataxia, and dysarthria
quickly disappeared after withdrawal of all three drugs.
When a seizure occurred, administration of oral pheny-
toin at home or, if oral phenytoin treatment failed, intra-
venous administration at the emergency department, both in
a dosage of 10 mg/kg, prevented clustering of seizures and
status epilepticus. With oxcarbazepine, valproic acid, lam-
otrigine, and clobazam maintenance therapy, seizure fre-
quency decreased to once weekly. Because of the success of
phenytoin as rescue medication, it was tried as maintenance
therapy. Unfortunately, this chronic use of phenytoin, even
at a 2 mg/kg/day dose, resulted in severe side effects,
including ataxia, dysarthria, and somnolence, and therefore
had to be withdrawn.
In search of successful maintenance therapy, we have
recently initiated the new sodium channel blocker
lacosamide. At a 2 mg/kg/day dose, he is already more alert
but still has weekly seizures for which he uses oral pheny-
toin (10 mg/kg) at home to prevent clustering of seizures,
thus status epilepticus and hospital stays. After a seizure, he
experiences 1–2 days of deterioration of his motor skills
and temporary loss of speech followed by dysarthria. Cur-
rently, he walks without assistance, is able to climb, jump,
and cycle with only a slight ataxia and hypotonia, and
attends a school for special education.
Discussion
This case demonstrates a favorable response to phenytoin
in status epilepticus as well as in the prevention thereof in a
patient with a SCN8A mutation. The use of phenytoin and
oxcarbazepine is counterintuitive in Dravet-like syndromes,
because patients with classic Dravet syndrome based on
SCN1A gene mutations deteriorate when treated with these
drugs.7,8 Phenytoin could be an important treatment option
in patients with SCN8Amutation-related epilepsy because it
is primarily expected to block the increased sodium current
through the mutated Nav1.6, but not to affect the function of
other voltage-gated sodium channels not affected by the
SCN8Amutation.3 Therefore, the diagnosis of SCN8Amuta-
tion is important for rational treatment decisions.
The potentially severe side effects of phenytoin, especially
cognitive impairment, are undesirable in patients with
SCN8A encephalopathy who already suffer from a delay in
cognitive development. Yet, this case demonstrates that there
may bemerit in using phenytoin as an emergency treatment.
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